FDA Approves Daytrana (methylphenidate transdermal system) CII for the Treatment of ADHD in Adolescents
Links shared publicly online about this topic.
- 1,037total visits
FDA Approves Daytrana (methylphenidate transdermal system) CII for the Treatment of ADHD in Adolescents
View full resource at drugs.com
Tags: ADHD, ADHD Medication, FDA, Concerta, Metadate CD, Metadate ER, Methylin, Ritalin
Most Recently Shared on July 8, 2010 at 7:20 pm By:
FDA Approves Daytrana for the Treatment of ADHD in Adolescents - http://bit.ly/aZ1hIE
Daytrana gains indication for attention deficit hyperactivity disorder (ADHD) in adolescents - MPR
empr.com — “The FDA has approved Daytrana (methylphenidate transdermal system, from Shire) for the treatment of attention deficit hyperactivity disorder (ADHD) in adolescents 13"17 years of age.” View full resource at empr.com
Most Recently Shared on July 7, 2010 at 3:13 pm By:
MPR News: Daytrana gains indication for attention deficit hyperactivity disorder (ADHD) in adolescents: The FDA ha... http://bit.ly/boPPmm
Shire receives FDA approval of Daytrana for ADHD in adolescents
news-medical.net — “Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include ” View full resource at news-medical.net
Most Recently Shared on July 7, 2010 at 5:40 am By:
Shire receives FDA approval of Daytrana for ADHD in adolescents: Shire plc, the global specialty biopharmaceutical... http://bit.ly/atTr4s
Advertisement
